Inclusive Dialogue and Compromise Needed to Address Major Issues Impacting Society Today, Reveals International Survey from Philip Morris International
The results of a new international survey released today by Philip Morris International Inc. (PMI) (NYSE: PM) reveal that citizens worldwide are frustrated by divisive and exclusionary approaches to policymaking. More than eight in ten adults surveyed worldwide (82 percent) believe the best solutions to critical global challenges can be found not at the extremes but in the middle ground. Conducted by independent research firm Povaddo for PMI, the survey of more than 44,000 adults in 22 countries shows strong agreement among respondents (88 percent) that when making decisions that affect the lives of a significant portion of the population, leaders must listen to and advocate for the people they represent.
The survey results show support for a balanced approach to tobacco regulation, one that brings together all voices and encourages incremental progress on harm reduction. Specifically, the survey found that:
- 77 percent agree that the too-often-ignored perspectives of those most directly impacted need to be included in regulatory discussions;
- 75 percent agree that societal expectations of total abstinence from substances such as nicotine and alcohol are not feasible, and so the government should take steps to reduce the harm of their use; and
- 72 percent agree that their governments need to consider the role alternative products can play in making their countries smoke-free.
“If we are to address the challenges we face as a society in a meaningful and expeditious way, a more balanced and inclusive approach is required,” said Gregoire Verdeaux, Senior Vice President, External Affairs. “This includes policy decisions that consider first and foremost the people who are most impacted—ensuring their voices are heard and their needs are met—and then bringing all relevant parties to the table, including subject matter experts, private companies, civil society leaders, and others who can contribute to solving the issues at hand.”
Despite increasingly polarized societies worldwide, the survey revealed a strong consensus that finding a middle ground on contentious issues can drive incremental policy change and enable progress:
- 90 percent of respondents believe that to solve the most pressing societal challenges, leaders need to consider all perspectives—even those that run counter to their own.
- 88 percent said they would be more likely to vote for leaders who listen to all sides of an issue and adopt sensible approaches that better the lives of ordinary people.
- Currently, less than a third of adults surveyed (31 percent) believe their views are reflected in the way their governments are addressing critical issues.
Additionally, the survey found that citizens are tired of waiting for change and are willing to compromise to make things happen:
- 76 percent believe leaders should pursue policy changes that allow for incremental progress on societal issues rather than hold out for sweeping changes that are harder to implement.
Finally, people want companies and business leaders to help drive change:
- 85 percent of respondents believe that citizens and companies working together will have a more meaningful impact.
- 77 percent welcome corporate involvement in addressing major issues.
Gregoire Verdeaux said: “In countries across the world, citizens are tired of policymaking logjams and eager for constructive change. In the area of tobacco harm reduction, PMI has long advocated for a sensible approach that prioritizes the interests of current adult smokers and public health. By having balanced and inclusive discussions about the science behind better alternatives and adopting a more people-centric approach, we can accelerate the end of cigarettes. More than a billion people continue to smoke. We must—and can—do better, and that starts with open, fact-based dialogue.”
For additional information and to access the full global data set, visit www.pmi.com/hearallvoices.
Survey Methodology
Povaddo conducted the online survey on behalf of PMI between February 5 and 23, 2022. The survey was fielded among 44,000+ general population adults aged 21 and older in 22 countries: Argentina, Brazil, Bulgaria, Colombia, Costa Rica, the Czech Republic, Dominican Republic, France, Germany, Greece, Italy, Japan, Malaysia, Mexico, the Philippines, Portugal, Serbia, South Africa, South Korea, Spain, the United Kingdom, and the United States. Around 2,000 interviews were conducted in each country (approximately equally split between adults who do and do not use nicotine-containing products). The data are weighted to be representative of the online population in each country on the following variables: age, gender, region, and nicotine use. The results are accurate to a margin of error of ±1 percent.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of preclinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as modified risk tobacco products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of March 31, 2022, PMI’s smoke-free products are available for sale in 71 markets, and PMI estimates that approximately 12.7 million adults around the world, excluding Russia and Ukraine, have already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005283/en/
Contact information
Philip Morris International
David Fraser
Philip Morris International
T. +41 (0)79 843 8603
E. david.fraser@pmi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 15:00:00 EET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 15:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argentina, Brazil, Chile, and Mexico, leveraging Debiopharm's proprietary DEBIO SPHERETMLong-Acting Release Platform technology and expertise in developing extended-release formulations to potentially reduce the freq
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 15:00:00 EET | Press release
IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations in more than 50 countries and partnerships with 18,000 growers and 300 retailers, IFCO’s scale enables
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 14:00:00 EET | Press release
The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what looks likely to be a very busy annual meeting season.” Produced in association with White & Case, a global law firm, thereport reveals that while smaller-cap companies accounte
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues to advance with sonrotoclax, a potentially best-in-class BCL2 inhibitor that has demonstrated impressive clinical results, and our BTK CDAC BGB-16673, further strengthening our leadership in B cell malignancies, including CLL. With one of the most promising oncology pipelines in the industry, we are poised to deliver multiple data and regulatory milestones that wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
